Trial Profile
Prospective Study of Rapamycin for the Treatment of SLE (Rapamune)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Jun 2023
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary)
- Indications Systemic lupus erythematosus
- Focus Pharmacogenomic; Therapeutic Use
- 24 Oct 2018 Results (n=84) assessing therapeutic response of rapamycin in systemic lupus erythematosus patients, presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
- 12 Oct 2016 Status changed from active, no longer recruiting to completed.
- 05 Feb 2015 Planned primary completion date changed from 1 Oct 2013 to 1 Dec 2015, as reported by ClinicalTrials.gov.